Endpoints News 13. Jan. 2026 Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Endpoints News 12. Jan. 2026 Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
FierceBiotech 9. Dez. 2025 Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech
Endpoints News 8. Dez. 2025 #ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?
BioPharma Dive 8. Dez. 2025 Terns drug shows potential to challenge Novartis’ blockbuster leukemia treatment
BioPharma Dive 26. Nov. 2025 Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3